Biologics | Biologics | Healthcare | Medical Devices | Patents

Michael is an Associate in the Life Sciences and Chemistry team specialising in biotechnology, therapeutics and diagnostics. He has particular expertise in the fields of antibody technology, cell culture, cell therapy, bioinformatics, computational biology, genomic medicine and synthetic biology. Michael enjoys working at the intersection of technology fields such as in digital healthcare and AI-driven drug discovery. 
He gained valuable in-house experience through a secondment to Kymab Ltd in 2020/2021. This enhanced his ability to help to solve in-house problems. This includes providing IP training, for which he received the following feedback from a company CEO:
“Thank you for coming up to do the IP training. Everyone agreed it was incredibly engaging and you turned what could have been a very dry topic into something very much alive. The team loved your style and you clearly have another career ahead of you as an after dinner speaker if the Patent attorney thing doesn't work out!”
He is nonetheless persisting with the day-job, which focusses on drafting and prosecuting patent applications, providing strategic advice on filing strategies and portfolio management, and coordinating international prosecution of complex patent portfolios. In addition, Michael is regularly involved in post-grant opposition procedures before the European Patent Office.
Michael’s PhD applied cell and molecular biology approaches to assess the role of one gene in the developing murine nervous system. Michael graduated with a First Class degree in Biochemistry from Southampton University, where he was awarded the 'Biochemistry Prize' for best aggregate performance.
Michael prides himself on providing pragmatic, commercially-minded advice, tailoring his guidance to suit each client.


European Patent Attorney
Chartered UK Patent Attorney
Certificate in Intellectual Property Law – Queen Mary University (2015)
PhD Integrative Neuroscience – Cardiff University (2013)
BSc (Hons) Biochemistry – University of Southampton (2008)


Chartered Institute of Patent Attorneys (CIPA)
The Institute of Professional Representatives before the European Patent Office (EPI)

Selected Publications

​​M. Newton, Destined for the digital scrap heap?, Kilburn & Strode, (2022)

​M. Newton, Solving in-house counsel challenges in European IP: Transatlantic teamwork, Kilburn & Strode, (2021)

​M. Newton, AI and Drug Discovery, Kilburn & Strode, (2020)

​M. Newton, AI Diagnostics and Digital Healthcare, Kilburn & Strode, (2020)

​M. Newton, AI in Drug Repurposing, Kilburn & Strode, (2020)

M. Newton, Patent eligibility of cultured cells in the US: A European perspective, Kilburn & Strode, (2019)

M. Newton, Differences in Culture: Expanded Cells Held Patent Eligible in the US. European Intellectual Property Review (2019) 41(2), 123-126

M. Newton Don't treat a subject; treat a disease, Kilburn & Strode (2018)

Vizard TN*, Newton M*, Howard L, Wyatt S, Davies AM. ERK signaling mediates CaSR-promoted axon growth. Neuroscience Letters (2015) 603:77–83. 
* These authors contributed equally to this work.

Albasser MM, Olarte-Sánchez CM, Amin E, Horne MR, Newton MJ, Warburton EC, Aggleton JP. The neural basis of nonvisual object recognition memory in the rat. Behavioral Neuroscience (2013) 127(1):70-85.

Hands S, Sajjad MU, Newton MJ, Wyttenbach A. In vitro and in vivo aggregation of a fragment of huntingtin protein directly causes free radical production. Journal of Biological Chemistry (2011) 286(52):44512-20.

Newton M, Niewczas I, Clark J, Bellamy TC. A real-time fluorescent assay of the purified nitric oxide receptor, guanylyl cyclase. Analytical Biochemistry (2010) 402(2):129-36.

Cookies improve the way our website works. By using this website you are agreeing to our use of cookies. For more information see our cookie policy I accept